secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009137
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q1 net loss $25.2M; cash $449.9M; TNG908 trial open
----------------------------------------------------------------------

- Net loss $25.2M ($0.29/share) vs $12.1M loss in Q1 2021; R&D expense $24.3M (+62% YoY).
- Cash, cash equivalents & marketable securities $449.9M; expected to fund operations into H2 2024.
- TNG908 Phase 1/2 trial open for MTAP-deleted solid tumors; FDA Fast Track Designation granted.
- Declared TNG462 (next-gen PRMT5 inhibitor) and TNG260 (STK11-loss inhibitor) as development candidates.
- Collaboration revenue $5.8M, down from $6.4M, due to lower Gilead research costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017022009137/0000950170-22-009137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017022009137/tngx-20220511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer